Yükleniyor... / Loading...
This is a national clinical-biological cohort study following patients newly diagnosed with aggressive fibromatosis, involving biopsy and biobank creation. It included patients in France diagnosed after 01/01/2016 whose diagnosis was confirmed, including screening for mutations in the CTNNB1 (β-catenin) gene. It is a non-phase study and is currently active but not recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Incident Case of aggressive fibromatosis in France, diagnosed after 01/01/2016 * Confirmed diagnosis by the French anatomopathological diagnosis network (including search for mutation of the β-Catenin Gene, CTNNB1) * Affiliation to the National Health System * Informed consent signed (both parents signature for non adult patients) Exclusion Criteria: * Administrative or legal measure of liberty privation * Patient not able to give consent or unwilling to provide consent